Daiichi Sankyo Co. Ltd., of Tokyo, reported through its European arm one-year outcomes results from a study of 24,962 patients with nonvalvular atrial fibrillation (NVAF) treated with Lixiana (edoxaban), including elderly NVAF patients and those with and without a history of intracranial hemorrhage.